Rhythm Pharmaceuticals Gains EMA Backing for IMCIVREE Expansion

Rhythm Pharmaceuticals ( (RYTM) ) has provided an announcement.

On March 26, 2026, Rhythm Pharmaceuticals reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion backing an expansion of IMCIVREE’s marketing authorization. The proposed label would cover treatment of obesity and control of hunger in adults and children aged four and older with acquired hypothalamic obesity caused by hypothalamic injury or impairment.

The opinion, which follows a recent U.S. Food and Drug Administration approval in the same indication, underscores a substantial unmet medical need in this rare neuroendocrine disorder and supports Rhythm’s strategy in precision obesity medicine. The recommendation now goes to the European Commission, whose decision expected in the second quarter of 2026 could significantly broaden IMCIVREE’s addressable patient population in Europe and reinforce the company’s positioning in rare obesity therapeutics.

The most recent analyst rating on (RYTM) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.

Spark’s Take on RYTM Stock

According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.

The score is driven primarily by improving financial fundamentals (strong revenue growth and high gross margins) and low balance-sheet leverage, but materially held back by ongoing net losses and continued cash burn. Technicals remain weak with the stock trading below key moving averages and a negative MACD. Recent updates are net-positive (notably FDA approval for acquired hypothalamic obesity and multiple catalysts), though higher guided operating spend and mixed Phase 3 expansion data add execution and funding-risk considerations.

To see Spark’s full report on RYTM stock, click here.

More about Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a Boston-based, commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead product, IMCIVREE (setmelanotide), is an MC4R agonist targeting hyperphagia and severe obesity, already approved in the U.S., European Union and U.K. for specific genetically driven and acquired forms of obesity in pediatric and adult populations.

Average Trading Volume: 786,379

Technical Sentiment Signal: Hold

Current Market Cap: $5.78B

See more insights into RYTM stock on TipRanks’ Stock Analysis page.